196 related articles for article (PubMed ID: 29196926)
1. Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.
Goethe E; Carter BZ; Rao G; Pemmaraju N
J Neurooncol; 2018 Jan; 136(2):223-231. PubMed ID: 29196926
[TBL] [Abstract][Full Text] [Related]
2. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
4. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
5. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
6. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
7. PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways.
Mu N; Gu J; Liu N; Xue X; Shu Z; Zhang K; Huang T; Chu C; Zhang W; Gong L; Zhao H; Jia B; Gao D; Shang L; Zhang W; Guo Q
Theranostics; 2018; 8(6):1527-1539. PubMed ID: 29556339
[No Abstract] [Full Text] [Related]
8. SPG6 supports development of acute myeloid leukemia by regulating BMPR2-Smad-Bcl-2/Bcl-xl signaling.
Chen J; Li C; Zhan R; Yin Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):220-225. PubMed ID: 29715457
[TBL] [Abstract][Full Text] [Related]
9. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
11. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
[TBL] [Abstract][Full Text] [Related]
12. New Directions in the Treatment of Glioblastoma.
Reitman ZJ; Winkler F; Elia AEH
Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
14. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
15. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
16. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
Chaurasia A; Park SH; Seo JW; Park CK
J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
[TBL] [Abstract][Full Text] [Related]
18. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
19. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations in myeloid cell leukemia-1 contribute to the pathogenesis of glioma by prolonging its half-life.
Lv X; Tan G; Yao Y; Lv L; Deng X; Dong L; Li S; Li L; Xu Y
Mol Med Rep; 2015 Jul; 12(1):1265-71. PubMed ID: 25777305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]